Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
AI

NASDAQ · AIDX

20/20 Biolabs, Inc. Common Stock

Healthcare · Medical - Devices

$0.38

Down-$0.00 (-1.06%)

Updated Oct 10, 2026, 9:05 AM

SID Score

2.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
18.77M
P/E ratio
-8.94
Dividend yield
0.00%
52-week range
$0.33 – $3.08
Volume
65.82K
Avg. volume
551.63K

Price performance · AIDX

AIDX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

AIDX closed at $0.38 after 21 trading sessions, down 33.04% for the selected period.

Last close
$0.38
Period change
-33.04%
Period low
$0.34
Period high
$0.56
Daily close
View OHLC price history
AIDX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$0.372$0.3947$0.3601$0.37565.82K
Oct 8, 2026$0.363$0.40$0.349$0.379187.12K
Oct 7, 2026$0.359$0.3594$0.342$0.343582.85K
Oct 6, 2026$0.3477$0.3622$0.336$0.352569.11K
Oct 5, 2026$0.40$0.40$0.331$0.3524119.88K
Oct 2, 2026$0.41$0.4274$0.3612$0.3865.8K
Oct 1, 2026$0.4302$0.4506$0.4089$0.408951.99K
Sep 30, 2026$0.4416$0.465$0.4123$0.436544.2K
Sep 29, 2026$0.4599$0.4599$0.409$0.4091102.99K
Sep 28, 2026$0.4347$0.4347$0.4035$0.40942.22K
Sep 25, 2026$0.43$0.4699$0.43$0.434760.84K
Sep 24, 2026$0.4275$0.43$0.4032$0.423180.96K
Sep 23, 2026$0.47$0.499$0.40$0.426677.71K
Sep 22, 2026$0.4695$0.50$0.4644$0.470533.68K
Sep 21, 2026$0.5099$0.5099$0.4515$0.469958.07K
Sep 18, 2026$0.4799$0.50$0.465$0.465131.76K
Sep 17, 2026$0.4606$0.4799$0.4601$0.471526.69K
Sep 16, 2026$0.4785$0.50$0.4601$0.480834.25K
Sep 15, 2026$0.5205$0.5315$0.4682$0.475833.58K
Sep 14, 2026$0.531$0.6084$0.514$0.520550.18K
Sep 11, 2026$0.56$0.5979$0.5301$0.5644.78K

Latest AIDX news

The latest Smart Investors Daily articles mentioning AIDX.

Stock researchCompany · Overview

AIDX research

Overview

Company profile and research snapshot.

Company profile

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
AIDX recent ratings
DateFirmRatingTarget
May 11, 2026Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026

Management to Hold One-on-One Meetings with Institutional Investors at the Hard Rock Hotel New York GAITHERSBURG, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that President and Chief Executive Officer Jonathan Cohen and Chief Financial Officer Alan Bergman will participate in the Maxim Growth Sum

Yahoo · Sep 29, 2026

20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model

President and CEO Jonathan Cohen to Discuss Implications for Multi-Cancer Early Detection, Preliminary Interest from Laboratories Across the United States, and New State Funding for Firefighter Cancer Screening Webinar to Be Held Wednesday, October 7, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tes

Yahoo · Sep 6, 2026

Profound Medical Stock And 2 Canadian AI Healthcare Stocks To Watch

Canada’s Ivey PMI recently hit a multi year high, hinting that businesses are spending again on tools that cut costs and raise productivity. That backdrop puts artificial intelligence in healthcare on many watchlists. AI can help Canadian hospitals and drug developers do more with limited budgets. This article walks through three AI focused healthcare stocks from our screener that could interest investors watching this shift. The stocks below are just a sample from this theme, and the full...

Yahoo · Sep 5, 2026

Healwell AI (TSX:AIDX) Stock Draws Fresh Price Target Split After Quarterly Results

Price targets for Healwell AI have been adjusted within a CA$1.50 to CA$2.00 range, with some analysts moving up to CA$2.00 and others trimming down to CA$1.50. This split reflects different views on how recent quarterly execution lines up with what investors should be willing to pay for the stock today. As you read on, you will see how to interpret these shifting targets and track the evolving narrative around Healwell AI for your own decision making. Analyst Price Targets don't always...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By